Kenneth Crook
Head of Translational Medicine Engimmune Therapeutics
Seminars
Wednesday 4th November 2026
Targeting Inflammation at the Source: Advancing ENGI-004 to Deliver Tissue-Selective Immune Modulation in Atopic Dermatitis
1:30 pm
- Exploring a novel tissue-targeted approach to immunomodulation by engaging MHC-related receptors enriched at barrier tissues, including the skin, to concentrate activity where disease occurs
- Leveraging AI-guided protein engineering to optimize efficacy and safety through precise delivery of inhibitory signals to inflamed tissues while minimizing systemic immune suppression
- Translating ENGI-004 from discovery toward clinical development to establish a differentiated therapeutic strategy for atopic dermatitis and other barrier tissue inflammatory diseases
Wednesday 4th November 2026
Panel Discussion: Competing Beyond Dupixent: Leveraging Unique Mechanisms of Action & Long- Acting Drugs to Differentiate in the Next Wave of Atopic Dermatitis Therapeutics
9:30 am
- Positioning new mechanisms of action such as IL-31 inhibition and long-acting drugs as a potentially best-in-class alternative in moderate-to-severe atopic dermatitis
- Assessing how infrequent maintenance dosing compares with Dupixent, Ebglyss and oral JAK inhibitors, improving convenience and long-term adherence potential, to strengthen differentiation in an increasingly crowded AD market
- Understanding whether deeper and sustained responses with highly selective IL-13 blockade can redefine competitive benchmarks for efficacy, safety and patient preference, aligning clinical outcomes with payer and physician expectations, to maximise uptake and commercial value ahead of planned Phase 3 initiation in 2H 2026
